含阿司匹林的碳酸酐酶9抑制剂克服缺氧诱导耐药增强心肌保护效果
An Original Aspirin-Containing Carbonic Anhydrase 9 Inhibitor Overcomes Hypoxia-Induced Drug Resistance to Enhance the Efficacy of Myocardial Protection
Zhou Wen, Zhang Bin, Fan Keyu, Yin Xiaojian, Liu Jinfeng, Gou Shaohua
Journal:CARDIOVASCULAR DRUGS AND THERAPY
IF:3.73
DOI:10.1007/s10557-021-07182-2
PMID:33844134
Published:2021-04-12
research field:抗菌药物耐药性传染病学质粒生物学分子流行病学微生物遗传学
Abstract
Purpose Hypoxic microenvironment plays a vital role in myocardial ischemia injury, generally leading to the resistance of chemotherapeutic drugs. This induces an intriguing study on mechanism exploration and prodrug design to overcome the hypoxia-induced drug resistance. Methods In this study, we hypothesized that the overexpression of carbonic anhydrase 9 (CAIX) in myocardial cells is closely related to the drug resistance. Herein, bioinformatics analysis, gene knockdown, and overexpression assay certificated the correlation between CAIX overexpression and hypoxia. An original aspirin-containing CAIX inhibitor AcAs has been developed. Results Based on the downregulation of CAIX level, both in vitro and in vivo, AcAs can overcome the acquired resistance and more effectively attenuate myocardial ischemia and hypoxia injury than that of aspirin. CAIX inhibitor is believed to recover the extracellular pH value so as to ensure the stable effect of aspirin. Conclusion Results indicate great potential of CAIX inhibitor for further application in myocardial hypoxia injury therapy.
本文使用的Yeasen产品
南美超级胎牛血清999尝鲜特惠


